Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dapsone and Tretinoin Gel for Facial Acne Vulgaris
NCT00835198Phase 4Completed
- Sponsor
- Allergan
- Start
- Dec 2008
- Primary completion
- Aug 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, single-blind trial of dapsone in acne vulgaris (2 arms), sponsored by Allergan. Primary endpoint: Change From Baseline in Inflammatory Lesion Counts (Papules, Pustules and Nodules) at 12 weeks. Started Dec 2008; status: completed.
02
Drugs
dapsone
03
Conditions
acne vulgaris
Beyond the preview
Go deeper on NCT00835198.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00835198.